托吡酯和左乙拉西坦对学龄期癫痫患儿骨代谢的影响

Effects of Topiramate and Levetiracetam on Bone Metabolism in school-age Children with Epilepsy

目的:分析探讨托吡酯和左乙拉西坦对学龄期癫痫患儿骨代谢水平的影响。方法:选取我院2014年10月至2017年10月收治的82例学龄期癫痫患儿进行研究,按照随机双盲法随机分为A组和B组,每组各41例。两组患儿分别采用托吡酯和左乙拉西坦治疗,对比两组患儿的临床疗效及对骨代谢功能的影响。结果:A组和B组患者临床治疗总有效率分别为87.80%(36/41)、90.24%(37/41),组间相比差异无统计学意义(χ~2=0.12,P>0.05);A组和B组患者治疗后不良反应发生率分别为、46.34%(19/41)、19.51%(8/41);组间相比差异具有统计学意义(χ~2=6.68,P<0.05);治疗后,A组患者血钙离子(Ca)、血磷离子(P)、碱性磷酸酶(ALP)、骨碱性磷酸酶(BAP)及骨密度(BMD)水平分别为[(2.46±0.09)mmo L/L]、[(1.47±0.07)mmo L/L]、[(183.68±26.54)U/L]、[(232.64±17.02)]、[(2.24±1.72)],B组患者治疗后各指标分别为[(2.45±0.10)mmo L/L]、[(1.46±0.08)mmo L/L]、[(184.12±24.83)U/L]、[(233.52±18.31)]、[(2.26±1.86)],两组治疗前后各指标相比差异无统计学意义(P>0.05)。结论:托吡酯和左乙拉西坦对学龄期癫痫患儿均具有良好的治疗效果,但托吡酯治疗过程中不良反应发生率较高,安全性较低;但两种药物短期内用药对患儿骨代谢均无明显的影响。

Objective:To investigate the effects of topiramate and levetiracetam on the bone metabolism in children with school-age epilepsy.Methods:A total of 82 cases of children with school-age epilepsy who were treated in our hospital from October 2014 to October 2017 were randomly divided into group A and group B,41 cases in each group.The two groups of children were treated with topiramate and levetiracetam,respectively.The clinical efficacy and the effect on bone metabolism were compared between the two groups.Results:The total effective rate of clinical treatment in group A and group B was 87.80%(36/41)and 90.24%(37/41)respectively,with no significant difference between the two groups(χ2=0.12,P>0.05)The incidence of adverse reactions in group B was 46.34%(19/41)and 19.51%(8/41)respectively after treatment.The difference between the two groups was statistically significant(χ2=6.68,P<0.05).After treatment,The levels of Ca,P,ALP,BAP and BMD in group A were(2.46±0.09)mmoL/L,1.47±0.07 mmoL/L,183.68±26.54 U/L,232.64±17.02 and 2.24±1.72,respectively.The indexes in group B were[(2.46±0.08)mmoL/L],[(184.12±24.83)U/L],[(233.52±18.31)]and[(2.26±1.86)]Before and after treatment,there was no significant difference between each index(P>0.05).Conclusion:Topiramate and levetiracetam have a good therapeutic effect on children with school-age epilepsy,but the incidence of adverse reactions is high and safety is low during the course of topiramate treatment.However,the short-term use of the two drugs on the bone metabolism No obvious effect.